Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK3 | P27361 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 12/20 | 0.37 |
| ▸ | JAK1 | P23458 | 12/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 2/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17837222 | 0.93 | MAPK3 (0.47) | MAPK3MAPK1JAK2JAK1IGF1R | |
| SCHEMBL17837165 | 0.91 | MAPK3 (0.45) | MAPK3MAPK1JAK2JAK1TYK2 | |
| SCHEMBL17837234 | 0.91 | MAPK3 (0.51) | MAPK3MAPK1JAK2JAK1LRRK2 | |
| SCHEMBL17837199 | 0.87 | MAPK3 (0.65) | MAPK3MAPK1JAK2JAK1 | |
| SCHEMBL17856232 | 0.85 | MAPK3 (0.51) | MAPK3MAPK1JAK2JAK1TYK2 | |
| Hydrochloric Acid SCHEMBL17837256 | 0.84 | MAPK3 (0.50) | MAPK3MAPK1JAK2JAK1TYK2 | |
| SCHEMBL17856225 | 0.84 | MAPK1 (0.45) | MAPK3MAPK1JAK2JAK1LRRK2 | |
| SCHEMBL17837238 | 0.80 | MAPK3 (0.54) | MAPK3MAPK1JAK2TYK2LRRK2 | |
| SCHEMBL17837208 | 0.80 | MAPK1 (0.58) | MAPK3MAPK1JAK2JAK1TYK2 | |
| SCHEMBL17837224 | 0.79 | MAPK3 (0.54) | MAPK3MAPK1JAK2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE48635-E1 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2021-07-13 | — | — | US | disclosed |
| EP-3237423-B1 | THIENO[2,3-C]PYRROL-4-ONE DERIVATIVES AS ERK INHIBITORS | LILLY CO ELI (US) | 2019-06-05 | — | — | EP | disclosed |
| EP-3237423-A1 | THIENO[2,3-C]PYRROL-4-ONE DERIVATIVES AS ERK INHIBITORS | Eli Lilly and Company (US) | 2017-11-01 | — | — | EP | disclosed |
| US-20160375030-A1 | ERK INHIBITORS | ELI LILLY AND COMPANY | 2016-12-29 | — | — | US | disclosed |
| US-9526733-B1 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2016-12-27 | — | — | US | disclosed |
| US-9469652-B2 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2016-10-18 | — | — | US | disclosed |
| WO-2016106029-A1 | THIENO[2,3-C]PYRROL-4-ONE DERIVATIVES AS ERK INHIBITORS | ELI LILLY AND COMPANY (US) | 2016-06-30 | — | — | WO | disclosed |
| US-20160176896-A1 | ERK INHIBITORS | ELI LILLY AND COMPANY | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160375030-A1 | ERK INHIBITORS | MAPK4, MAPK1, MAPK3 | MAPK3 3/4885MAPK1 2/4885JAK2 146/4885 |
| US-20160176896-A1 | ERK INHIBITORS | MAPK4, MAPK1, MAPK3 | MAPK3 3/4885MAPK1 2/4885JAK2 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.